GBA1 and dementia: While α-synuclein and amyloid/tau biomarkers have not been validated in ADHD populations, studies in neurodegenerative disorders indicate that GBA gene mutations and APOE-ε4, particularly in carriers, are associated with accelerated cognitive decline and dementia onset (Szwedo et al., 2022).